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Genome Conference Offers Insights about the Future
of Medicine
__________________________________________
This past fall in San Diego, California, national biomedical and healthcare experts
gathered to tackle a tough question: Now that the Human Genome Project (HGP) has
provided a blue-print of our genetic code, what is the future of healthcare? During
the TJU-sponsored conference, Insights: The Human Genome Project and the Future
of Healthcare, speakers and audience members theorized about the potential
usefulness and impact of the human genetic code. Insights conference speakers said
that despite the hype generated when the completion of the human genome
sequence was announced in June 2000, we are only at the very edge of the new
frontier of biomedical science. The purpose of the conference was to imagine what
might come next.
CONFERENCE HIGHLIGHTS: WHAT THE EXPERTS HAVE TO SAY
The diversity of the eight presenters at the Insights conference provided a broad
view of the Human Genome Project and its implications. The group included a
healthcare futurist, two HGP researchers, two clinical pharmacologists leading
genomic research studies, a biotech investment expert, a former managed care
director who made the jump to biotechnology, and a nationally known bioethicist.
This section highlights the key messages each of the speakers offered.
Predictions for the Future
Russell C. Coile, Jr.: Senior Vice President/National Strategy Advisor, Superior
Consultants, Plano, Texas.
Future developments could include gene-based diagnostics, an accelerated FDA
approval process, cell and tissue engineering for organ replacement, and microscopic
surgery with nanotechnology robotics.
The Science and History of the Human Genome Project
George Weinstock, PhD: Co-Director, Human Genome Sequencing Center, Baylor
College of Medicine; Department of Microbiology and Molecular Genetics, University
of Texas-Houston Medical School.
Gwen Acton, PhD: Assistant Director, Functional Genomics Program, Whitehead
Institute/MIT Center for Genome Research, Cambridge, Massachusetts.
The ultimate objective of the human genome project was “to determine the precise
sequence of each of the 3 billion letters that make up the DNA strand.” A complete
and accurate identification and sequence for the human genome could facilitate a
better understanding of human life processes and offer the potential to cure many
diseases.
Applying The Human Genome Project in Clinical Pharmacology
Scott A. Waldman, MD, PhD: Chief, Division of Clinical Pharmacology, Thomas
Jefferson University.
David Flockhart, MD, PhD: Director, Pharmacogenetics Core Laboratory, Division of
Clinical Pharmacology, Georgetown University Medical Center, Washington, DC.
The HGP provides the basis for scientific development in three major areas: (1)
developing gene replacement therapy; (2) predicting individual patient responses to
drugs; and (3) applying functional genomics to find new drug targets. Dr. Waldman
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has identified a gene that is highly associated with development of cancer: the
guanylyl cyclase C (GCC) gene. His research has potential to lead to improved
treatments for colorectal cancer. Dr. Flockhart has focused his research on using
genes that relate to specific drug response, identifying who is most likely to have
positive therapeutic outcomes and, conversely, who might develop potential side
effects from particular medications.
The Human Genome Project and Managed Care
Grant D. Lawless, MD, RPh: Thousand Oaks, California.
Novel products created through pharmacogenomics will probably lead to novel
pressures for payment, in large part shouldered by managed care organizations
(MCOs). Even now, the percentage of the total healthcare dollar spent on drugs
concerns most payers. As high-tech drugs become more available in clinical practice,
direct drug costs and pharmacy budget costs will rise even further. Today, many
managed care organizations are willing to pay for more expensive drugs if there is a
guaranteed positive health outcome. In the future, pharmaceutical and biotech
industries alike will be expected to demonstrate this same clear improvement in
clinical medicine if high-tech genomic-based medications are to be covered.
The Wall Street Perspective
Sushant Kumar, PhD: Mehta Partners LLC New York, New York.
From Wall Street’s perspective, biopharmaceuticals are a good business investment,
particularly in response to today’s favorable social and economic environment. Our
aging population will increase market demand, as will the dynamic emerging
economies around the world. The current healthcare environment, based
predominantly on managed care, also enhances the economic value of
pharmaceuticals: MCOs rely heavily on drugs as their most cost-effective care
option.
Ethical Issues
Paul R.Wolpe, PhD: Faculty Associate, Center for Bioethics, University of
Pennsylvania; Chief Bioethicist, National Aeronautics and Space Administration
(NASA).
The public understands that genomics is going to be significantly beneficial, but they
also fear that the thought leaders driving the genomic revolution do not recognize
any downside of the science they are creating. The public is deeply ambivalent about
genetic advancement. There are five primary fears the public harbors concerning
genetic research:
1. Genomics has the potential to harm individuals and society.
2. Genomics will give rise to new forms of discrimination.
3. Genomics will jeopardize individual rights to privacy and confidentiality.
4. Genomics will result in detrimental environmental impacts.
5. Genomics will exceed the limits of acceptable human intervention.
Whether these fears are realized will be determined by how the ethics of genomics
are handled by everyone involved. Dr. Wolpe believes that the time for prophylactic
ethics is now.
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Copies of the proceedings are available by request. Please contact The Office of
Health Policy and Clinical Outcomes at (215) 955-6969.
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